The FLEX study will investigate current and future breast cancer questions through
linking full genome data with therapeutic interventions and long-term follow-up.
It will allow investigators to submit proposals for sub-studies within the FLEX study framework.All participating sites can interrogate the large, multi-institutional patient cohort through network-wide participation.
“FLEX has the potential to become one of the most valuable and impactful national datasets in breast cancer research – a veritable ‘Google’ for combined clinical and genomic breast cancer information”
– Dr Joyce O’Shaughnessy, M.D., Chair, Breast Cancer Program, US Oncology, Texas Oncology and Celebrating Women Chair in Breast Cancer Research, Baylor University Medical Center, Dallas, TX
WHICH OF MY PATIENTS ARE ELIGIBLE FOR FLEX?
Both female and male breast cancer patients in the United States diagnosed with stage I, II, or III cancer, who receive MammaPrint (with or without BluePrint) can participate, including all molecular sub-types and regardless of treatment or response to treatment.
Data collection is patient-centered, will be agnostic to management plans and regimens and participation will span the full cycle of care: diagnosis, treatment, follow-up.
By capturing genomic and clinical data from all ethnicities, ages, genders, and from patients with co-morbidities, the FLEX database will represent a ‘real-world’, truly representative patient population.
This includes many patients who may have been ineligible for inclusion in traditional clinical trials and those with rarer forms of breast cancer, an area where the ability of genomic signatures to stratify these cancers is still generally untested.
The first milestone for the revolutionary database will be to capture full genomic and clinical data for up to 10,000 breast cancer patients and follow them over 10 years.
HOW CAN I GET INVOLVED?
Since beginning enrollment in 2017, FLEX has 45 centers in the U.S. and has recruited over 700 patients.
To find out more about how to become a FLEX clinical site and enroll your patients in the study, simply email us at FLEX@agendia.com
If you are a breast cancer patient interested in participating in FLEX, please contact your physician.
For more information, click here or visit the FLEX resource page at www.clinicaltrials.gov for details on participating centers.
* BluePrint is a laboratory-developed test that was developed, validated and performed exclusively by Agendia